ReviewMarine drugs2017
Marine-Derived 2-Aminoimidazolone Alkaloids. Leucettamine B-Related Polyandrocarpamines Inhibit Mammalian and Protozoan DYRK & CLK Kinases.
Open access · goldAbstract readReview
In one paragraph
Review in Marine drugs, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 18% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- A Systematic Review of Recently Reported Marine Derived Natural Product Kinase Inhibitors.Marine drugs · 2019Pooled it
- Mapping the Brain Interaction Network of the Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) Targeted by Leucettinib-21 Using Affinity Chromatography.ACS pharmacology & translational science · 2026Article
- Leucettamine B and nacryline derivative promote the first steps of endochondral ossification in vitro.Scientific reports · 2026Article
- DYRK1A inhibition restores pancreatic functions and improves glucose metabolism in a preclinical model of type 2 diabetes.Molecular metabolism · 2025Article
- Article
- Chemical Investigation of the Calcareous Marine SpongeMarine drugs · 2024Article
- Natural Bioactive Compounds from Marine Invertebrates That Modulate Key Targets Implicated in the Onset of Type 2 Diabetes Mellitus (T2DM) and Its Complications.Pharmaceutics · 2023Review
- Cdc2-like kinases: structure, biological function, and therapeutic targets for diseases.Signal transduction and targeted therapy · 2023Review
- Natural Alkaloids as Multi-Target Compounds towards Factors Implicated in Alzheimer's Disease.International journal of molecular sciences · 2023Review
- Article
- Regeneration of Pancreatic β-Cells for Diabetes Therapeutics by Natural DYRK1A Inhibitors.Metabolites · 2022Review
- An Aminopyrimidone and Aminoimidazoles Alkaloids from the Rodrigues Calcareous Marine SpongeMarine drugs · 2022Article
- Pharmacological Activities of Extracts and Compounds Isolated from Mediterranean Sponge Sources.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Design and Microwave Synthesis of New (5Pharmaceuticals (Basel, Switzerland) · 2021Article
- Bioactive natural products from marine sponges belonging to family Hymedesmiidae.RSC advances · 2021Review
- Review
- 40 Years of Research on Polybrominated Diphenyl Ethers (PBDEs)-A Historical Overview and Newest Data of a Promising Anticancer Drug.Molecules (Basel, Switzerland) · 2021Review
- Review
- The preparation of (4H)-imidazol-4-ones and their application in the total synthesis of natural products.Organic chemistry frontiers : an international journal of organic chemistry · 2020Article
- [Molecules (Basel, Switzerland) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 5 institutions in 4 countries.
Nadège LoaëcManRos Therapeutics, Perharidy Research Center, 29680 Roscoff, Bretagne, France. nadege.loaec@univ-brest.fr.
Eletta AttanasioManRos Therapeutics, Perharidy Research Center, 29680 Roscoff, Bretagne, France. attanasio@manros-therapeutics.com.
Benoît VilliersManRos Therapeutics, Perharidy Research Center, 29680 Roscoff, Bretagne, France. bvilliers@yahoo.fr.
Emilie DurieuManRos Therapeutics, Perharidy Research Center, 29680 Roscoff, Bretagne, France. durieu@manros-therapeutics.com.
Tania TahtouhManRos Therapeutics, Perharidy Research Center, 29680 Roscoff, Bretagne, France. tania.tahtouh@gmail.com.
Morgane CamManRos Therapeutics, Perharidy Research Center, 29680 Roscoff, Bretagne, France. cam.morgane@live.fr.
Rohan A DavisGriffith Institute for Drug Discovery, Griffith University, Brisbane, QLD 4111, Australia. r.davis@griffith.edu.au.ORCID 0000-0003-4291-7573
Aline AlencarUniversidade Federal do Rio de Janeiro, Instituto de Biologia-Departamento de Zoologia, Av. Carlos Chagas Filho 373-CCS-Bloco A-Sala A0-100, Ilha do Fundão, 21941-902 Rio de Janeiro, Brasil. aalencar@biologia.ufrj.br.
Mélanie RouéMolécules de Communication et Adaptation des Micro-Organismes, UMR 7245 CNRS, Muséum National d' Histoire Naturelle, 57 rue Cuvier (C.P. 54), 75005 Paris, France. mroue@mnhn.fr.
Marie-Lise Bourguet-KondrackiMolécules de Communication et Adaptation des Micro-Organismes, UMR 7245 CNRS, Muséum National d' Histoire Naturelle, 57 rue Cuvier (C.P. 54), 75005 Paris, France. bourguet@mnhn.fr.
Peter ProkschInstitut für Pharmazeutische Biologie und Biotechnologie, Universitätsstr. 1, 40225 Düsseldorf, Germany. proksch@duesseldorf-uni.de.
Emmanuelle LimantonUniversité de Rennes 1, Institut des Sciences Chimiques de Rennes, ISCR UMR CNRS 6226, Groupe Chimie Organique et Interfaces (CORINT), Bât. 10A, Campus de Beaulieu, Avenue du Général Leclerc, CS 74205, 35042 Rennes CEDEX, Bretagne, France. emmanuelle.limanton@univ-rennes1.fr.
Solène GuiheneufUniversité de Rennes 1, Institut des Sciences Chimiques de Rennes, ISCR UMR CNRS 6226, Groupe Chimie Organique et Interfaces (CORINT), Bât. 10A, Campus de Beaulieu, Avenue du Général Leclerc, CS 74205, 35042 Rennes CEDEX, Bretagne, France. solene.guiheneuf@univ-rennes1.fr.
François CarreauxUniversité de Rennes 1, Institut des Sciences Chimiques de Rennes, ISCR UMR CNRS 6226, Groupe Chimie Organique et Interfaces (CORINT), Bât. 10A, Campus de Beaulieu, Avenue du Général Leclerc, CS 74205, 35042 Rennes CEDEX, Bretagne, France. francois.carreaux@univ-rennes1.fr.
Jean-Pierre BazureauUniversité de Rennes 1, Institut des Sciences Chimiques de Rennes, ISCR UMR CNRS 6226, Groupe Chimie Organique et Interfaces (CORINT), Bât. 10A, Campus de Beaulieu, Avenue du Général Leclerc, CS 74205, 35042 Rennes CEDEX, Bretagne, France. jean-pierre.bazureau@univ-rennes1.fr.
Michelle KlautauUniversidade Federal do Rio de Janeiro, Instituto de Biologia-Departamento de Zoologia, Av. Carlos Chagas Filho 373-CCS-Bloco A-Sala A0-100, Ilha do Fundão, 21941-902 Rio de Janeiro, Brasil. mklautau@biologia.ufrj.br.
Laurent MeijerManRos Therapeutics, Perharidy Research Center, 29680 Roscoff, Bretagne, France. meijer@manros-therapeutics.com.ORCID 0000-0003-3511-4916
Centre National de la Recherche Scientifique · FRManRos Therapeutics (France) · FRUniversidade Federal do Rio de Janeiro · BRGriffith University · AUHeinrich Heine University Düsseldorf · DE
Funding
No grant is acknowledged in the PubMed record.
Abstract
A large diversity of 2-aminoimidazolone alkaloids is produced by various marine invertebrates, especially by the marine Calcareous sponges
Indexed as
AlkaloidsAlzheimer DiseaseAminesAnimalsAntiprotozoal AgentsDown SyndromeDyrk KinasesHumansImidazolesPhosphorylationPhylogenyPoriferaProtein Kinase InhibitorsProtein Serine-Threonine KinasesProtein-Tyrosine KinasesProtozoan Infections2-aminoimidazoloneAlkaloidsAminesAntiprotozoal AgentsClk dual-specificity kinasesDyrk KinasesImidazolesleucettamine Bpolyandrocarpamine Apolyandrocarpamine BProtein Kinase InhibitorsProtein Serine-Threonine KinasesProtein-Tyrosine KinasesProtozoan Proteins2-aminoimidazolone alkaloidsAlzheimer’s diseaseascidianCalcareaCLKDown syndromeDYRKkinase inhibitorleucettamine Bleucettinemarine spongePolyandrocarpapolyandrocarpaminesPoriferaprotein kinases
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.